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ABSTRACT
Background: Estimation of cost-effectiveness of a therapy as compared with another, in healthcare, is often
based on a single perspective and a single time horizon. In this thesis, I explored methods of extrapolating
the survival effect of different interventions and the effect of time horizon on incremental cost-effectiveness
ratios when comparing two strategies.
Methods: Two strategies for a patient are compared: new or usual treatment. A hypothetical model based on
US life tables (for a 64-year old) assumed that the new and usual treatment strategies resulted in patient
survivals identical to a person who is 5 and 10 years older, respectively, than the patient's chronologic age.
The hazard rates over time were calculated and transformed to linear equations for least-squares linear
regression to fit exponential, linear exponential, Weibull and Gompertz distributions. The survival model
yielding the maximal likelihood estimate was extrapolated over different time horizons: 5, 10 and 15-year in
addition to lifetime. In addition, I extracted survival data from a published trial evaluating thrombolysis in
patients with myocardial infarction and applied this methodology over different time horizons. Finally, I
developed a matrix of incremental cost-effectiveness ratios over different time horizons, based on an
overview model, examining alternative assumptions when the cumulative difference in cost and
effectiveness of the two strategies: 1) decrease 2) remain constant or 3) increase. I used a statistical
programming language "R" for evaluation and analysis.
Results: When considering a US life-table based hypothetical model, Gompertz curve was the best-fitting
model. A linear-exponential model had the best fit when considering a survival model of thrombolysis
patients. A matrix of incremental cost-effectiveness ratios with decreasing, constant and increasing
cumulative difference in cost and effectiveness showed considerable change in incremental cost-
effectiveness ratios over different time horizons. The magnitude of effect of time horizon was flattened with
increasing discount rate for future cumulative differences in cost and effectiveness. With the exception of
similarly behaving and proportionate cumulative difference in cost and effectiveness leading to unchanged
incremental cost-effectiveness ratios, incremental cost-effectiveness ratios decreased when cumulative
difference in effectiveness increased and increased when cumulative difference in effectiveness decreased,
irrespective of behavior of cumulative difference in costs.
Conclusions: When conducting cost-effectiveness analysis of two competing strategies, choice of time
horizon has a substantial effect. Incremental cost-effectiveness ratio changes considerably with changes in
duration of time horizon. Discounting flattens the effect of time horizon in cost-effectiveness analysis. Care
must be taken in choosing the time horizon in a cost-effectiveness analysis and alternative time horizons
must be evaluated in all cost-effectiveness analyses.
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1. INTRODUCTION
1.1 Significance
With advances in technology and healthcare, new interventions are constantly being evaluated and compared
with existing interventions. The evaluation of health interventions is usually based on a single perspective
or a single time horizon e.g. societal perspective [1, 2] or a patient's lifetime [3, 4] is often used. However,
evaluations based on different time horizons and different perspectives may provide a better understanding
of costs and health outcomes for the different stakeholders involved. In addition, clinical trials are being
conducted to study the effectiveness of different interventions. As the costs of conducting these trials are
increasing, study investigators have an increased interest in the role of the time interval of trials, the duration
of intervention and the duration of effectiveness from the intervention in such health economic evaluations.
Cost-effectiveness analysis (CEA) is a methodology used to evaluate interventions in healthcare on the basis
of outcomes and costs of individual interventions. cost-effectiveness analysis involves estimating net or
incremental costs and effectiveness of an intervention and comparing it with an alternative intervention. The
comparison may be between two different interventions or use and no use of an intervention or two different
intensities of intervention. The cost-effectiveness ratio comparing the two alternatives is calculated as the
difference in costs between the alternatives divided by the difference in health outcomes. Commonly, cost-
effectiveness analyses are done on the entire lifetime based on yearly subunits. However, evaluating cost-
effectiveness based on different time horizons may give different results.
Tlhe time horizon of the cost-effectiveness analysis should extend far enough into the future to capture the
economic costs and major health outcomes including intended effects and unintended side effects. As a
result, many cost-effectiveness analyses are done over the duration of patients' life. However, some
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interventions may have a smaller duration of effectiveness or due to budgetary constraints, one is interested
in cost-effectiveness of an intervention over a shorter interval of time. As the appropriate time horizon of
cost-effectiveness analysis may extend beyond the availability of primary data, extrapolated or modeled data
are fiequently used. In fact, Gold et al. [5] recommends analyzing data using several time horizons. A
short-term horizon can be used for primary data while a long-term horizon can also include extrapolated
data. For example, Mark et al. [2] evaluated thrombolytic interventions during myocardial infarction over
1--year trial duration as well as a long-term horizon by modeling additional 14-year survival based on Duke
Cardiovascular Disease Database and further extrapolated it to a lifetime horizon using a fitted Gompertz
function. In addition, modeling should be used to estimate gains in life expectancy due to differential
survival. Therefore, extrapolation of analysis should be done far enough to capture important life saving
effects. For example, cholesterol-lowering program conducted for 5 years captures only 10% of the benefit
and the effectiveness should be extrapolated to achieve a realistic cost-effectiveness [6].
1.2 Objectives
The objective of this study is to
1. Explore methods of extrapolating the survival effect of different interventions
2. Evaluate the effect of time horizon on incremental cost effectiveness ratios
8
2. BACKGROUND
2.1 Approaches to economic evaluation of healthcare
There are two major approaches used in economic evaluation of health care [7]. The first approach of
economic evaluation involves measuring economic costs and health outcomes in a randomized controlled
trial as end points. This approach relies on the strengths of randomized trials that include prospective,
complete data collection; a rigorous protocol; and the use of random assignments to different interventions.
This helps to eliminate selection bias and to balance patient characteristics affecting outcomes. The
advantages of this approach are the use of consistent and direct data. The clinical outcomes data are obtained
from the same patient populations in a clinical trial rather than different trials or data sources. Additionally,
the economic and clinical outcomes are measured directly, with few assumptions and minimal modeling.
However, the simplicity of this approach leads to a few distinct disadvantages. Trial-based economic
analyses do not include the results of the other pertinent trials and lack the totality of evidence about a given
treatment. Studies with small sample sizes may give unreliable estimates of economic and clinical outcomes.
Protocol-driven care in trials may mandate deviation from usual clinical practice and distort resource
utilization and render economic analyses unsuitable. Finally, patients enrolled in trials may be highly
selected and not representative of patients in routine clinical practice, making the cost-effectiveness
calculation a best-case scenario.
The second major approach involves using a model to project the costs and clinical outcomes of alternative
strategies. The models based on this approach are usually sophisticated and base projections on the best
available evidence from a variety of sources. Therefore, the models using costs and health outcomes based
on meta-analyses of randomized clinical trials or on large, representative patient cohorts are considered more
credible. The advantages of this approach include the flexibility to examine cost-effectiveness under
different assumptions about risk, benefit, and cost, and to consider the implication of a strategy in different
9
groups of patients. The disadvantages of these models include the need to synthesize information from
disparate sources with inconsistent or biased data. Furthermore, the complexity and sophistication of these
models may make them less transparent, limiting peer review and independent verification of the findings.
In addition, these models may have been extrapolated beyond the empirical data without explicit recognition
that this has occurred.
In practice, these alternative approaches to economic evaluation are not mutually exclusive. Increasingly,
economic models are developed based on a particular trial data extrapolated with appropriate data from a
longer duration clinical trial database [2]. This hybrid approach allows the investigator to project results of
various alternatives not tested in the trial or to highlight strategies not evaluated directly.
2.2 Methods of economic analysis in healthcare
Cost-identification analysis (cost analysis): It is a type of economic analysis that only accounts for the
relevant resources and associated costs incurred by a given disease, treatment, healthcare technology or
strategy. The analysis does not assess health benefits for alternative strategies. It is implicitly assumed that
the outcomes are the same for the strategies in consideration and the optimal strategy can be identified by
choosing the cheapest strategy. Cost-identification, thus, measures the economic burden of a treatment or
strategy and the results apply to a specified cohort or population in a particular context.
Cost-benefit analysis (CBA): It is a form of economic-efficiency analysis in which both the costs and
outcomes (health benefits) are expressed in the same unit, as a single attribute, typically in monetary terms.
A monetary value of human life is calculated usually by the human capital method based on lost earnings or
willingness to pay method based on willingness to pay to decrease risk for death or disease. The optimal
strategy is the one with highest net benefit (benefit minus cost). This is more commonly used in the business
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world. However, the disadvantage of willingness to pay methodology is that it is heavily influenced by
ability to pay, on the conundrum of assigning an economic value to human life or life years.
Cost-effectiveness analysis (CEA): This form of economic-efficiency analysis involves valuing costs in the
same unit, e.g., dollars or monetary terms and valuing health benefits in the same unit, e.g., years or natural
units. However, it differs from cost-benefit analysis as it uses another single attribute - the unit for
measurement of cost is different from the unit for measurement of health benefits. An incremental cost-
effectiveness ratio compares differences in cost and effectiveness of some treatment strategy or new
healthcare technology of interest with a relevant alternative. However, besides comparing the strategies, it
allows one to choose a strategy for funding that falls beneath a cutoff expenditure per life year gained. This
analysis is more widely used in medicine.
Incremental Cost-Effectiveness Ratio (ICER) = (Cost New treatment - Cost Usual treatment)
(Effectiveness New treatment - Effectiveness Usual treatment)
Table 1: Cost-effectiveness comparison of strategies N and U [8]
Cost
N>U
N=U
N<U
CER = cost-effectiveness ratio, N = new treatment, U = usual treatment
As displayed in Table 1, cost-effectiveness analysis is useful when the new treatment strategy costs more
and is more effective than usual treatment strategy or when the new treatment strategy costs less and is less
effective than usual treatment strategy. A negative cost-effectiveness ratio, however, does not distinguish
between a more expensive and less effective or a less expensive and more effective strategy. Similarly, a
positive cost-effectiveness ratio does not distinguish between a less costly and less effective or a more
expensive and more effective strategy.
11
Health Outcome
N>U N=U N<U
Calculate incremental CER U less expensive: choose U U dominates N: choose U
N better outcome: choose N Makes no difference U better outcome: choose U
N dominates U: choose N N less expensive: choose N Calculate incremental CER
--- I
In its most common form, a new strategy is compared with current practice (the "low-cost alternative") in
the calculation of the cost-effectiveness ratio. The result might be considered as the "cost" of the additional
outcome purchased by switching from current practice to the new strategy (e.g., $8,000 per life year gained).
If the price is low enough, the new strategy is considered "cost-effective." Cost-effective interventions either
improve a health outcome and save money in the process or provide a health benefit at an "acceptable" cost.
"Acceptable" means what the decision-maker is comfortable paying for an improvement in outcome. Given
this definition, the following common misunderstandings are clarified. Cost-effectiveness is not equivalent
to effectiveness, which only involves health benefits. Cost-effectiveness does not mean cost saving, because
the lowest cost option is not necessarily the most cost-effective when both the relative benefit and cost are
considered. Naturally, if an intervention is more effective and costs less than an alternative strategy, then the
intervention should be pursued and is considered to be dominant.
Cost-utility analysis (CUA): It is a variant of cost-effectiveness analysis in which the health benefits include
quality of life adjustments. The health benefits are expressed in a scale that incorporates both longevity and
patient preferences (utilities) for the health states produced. Dollars per quality adjusted life year (QALY)
added is the most common form of cost-utility ratio in the medical literature.
When choosing between multiple mutually exclusive treatment options, it is common to construct a cost-
effectiveness frontier on the cost-effectiveness plane that represents efficient points from among the
treatment choices. Dominance of an alternative strategy exists when other strategies are cheaper and more
effective and are on the cost-effective frontier. Similarly, extended dominance of an alternative strategy
exists when other strategies are more expensive and have lower incremental cost-effectiveness ratios and are
on the cost-effectiveness frontier. Cost-effectiveness frontier can be estimated, when considering multiple
alternatives, either graphically or in a tabular form.
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Figure 1: Cost-effectiveness frontier
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Graphical Method: Costs are plotted on the y-axis while effectiveness of different strategies are plotted on
the x-axis. A cost-effectiveness frontier can be obtained by graphing a series of line segments connecting
every two non-dominated alternatives. The frontier slope becomes steeper as one moves from less expensive
to more expensive non-dominated alternatives. As shown in Figure 1, all alternatives not on the cost-
effectiveness frontier "lose" to alternatives on this frontier e.g. B and C fall above and to the left of the
frontier. These treatment options are considered inefficient and are excluded either by dominance, e.g. B,
(line BA connecting to the frontier has a negative slope) or by appealing to the principle of extended
dominance, e.g. C, (line AC has a greater positive slope while emanating from A on the cost-effectiveness
frontier). This representation of costs on the y-axis and effectiveness on the x-axis helps in easy visualization
of a cost-effectiveness analysis along with concepts of dominance and extended dominance as the slope of
the line represents incremental cost-effectiveness ratio for the competing strategies.
Tabular Method: Arrange alternatives from least expensive to most expensive in a table as in Table 2a. If
any of the alternatives is out of increasing order for total effect, it is dominated and should be removed.
Therefore, alternative B is eliminated by dominance. Then, calculate incremental costs for all alternatives
other than the least expensive. Doing nothing with no cost and no effect is not assumed to be an option.
13
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Table 2a: Calculating incremental cost-effectiveness ratios
Total Total Incr. Incr.
Alternative cost effect cost effect ICER
A 100 3
B 200 2 100 -1 -100
(C 400 4 200 2 100
ID 450 4.5 50 0.5 100
Remove B due to dominance (of A)
Incr.= Incremental, ICER = Incremental cost-effectiveness ratio
Then, incremental effectiveness for all alternatives other than the least expensive and all incremental cost-
effectiveness ratios are calculated. Starting from the least expensive, one eliminates any alternative that is in
the middle of three, if the incremental cost-effectiveness ratio comparing first (A) and second (C)
alternatives is larger than the incremental cost-effectiveness ratio comparing the second (C) and third (D)
alternatives in Table 2b. Alternative C is thus eliminated by extended dominance. Continue the process
mLoving down the table. One moves from least to most expensive, least to most effective, and lowest to
highest incremental cost-effectiveness ratio. Only two alternatives remain in this example.
Table 2b: Calculating incremental cost-effectiveness ratios and cost-effectiveness frontier
Total Total Incr. Incr.
Alternative cost effect cost effect ICER
A 100 3
(_ 400 4 300 1 300
D 450 4.5 50 0.5 100
Remove C due to extended dominance (of D)
Total Total Incr. Incr.
Alternative cost effect cost effect ICER
A 100 3
[) _ 450 4.5 350 1.5 233
Incr.= Incremental, ICER = Incremental cost-effectiveness ratio
Accounting for Uncertainty: Cost-effectiveness analysis is subject to uncertainty. However, when
uncertainty is considered, options excluded under the baseline analysis may form part of the cost-
effectiveness frontier. Three categories of uncertainty as described by Briggs et al. [9] relate to observed
data inputs, extrapolation and the analytic methods used. Cost-effectiveness acceptability curves [10] are
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used to represent the uncertainty concerning the cost-effectiveness of a health care intervention in the
context of decisions involving two interventions, as an alternative to confidence intervals around
incremental cost-effectiveness ratios. These curves provide a graphical representation of the probability that
a particular intervention is optimal over a range of values.
The economic evaluation should be subjected to sensitivity analysis. Probabilistic sensitivity analysis [11] is
preferred to the more limited one-way sensitivity analysis. For example, probabilistic sensitivity analysis,
using a large number of Monte Carlo simulations can be used to examine the effects on the results of an
economic evaluation when the underlying variables are allowed to simultaneously vary across a plausible
range of predefined distributions. By adopting a Bayesian approach, where distributions for model
parameters are specified, uncertainty in the decision concerning which treatment option should be
implemented is addressed directly. Such distributional models are preferred to pure deterministic models as
they facilitate the use of cost effectiveness acceptability curves to demonstrate cost-effectiveness.
2.3 Time horizon
Time horizon is the length of time into the future considered in the analysis over which costs and
effectiveness are projected. Depending on the perspective and clinical situation, the patient outcomes and the
costs involved may be relevant over different time horizons. For an employer, the costs incurred and clinical
outcomes obtained are relevant over the duration of employment while for a patient the outcomes are
relevant over an individual's lifetime. Similarly, the time horizon in a clinical setting may depend on the
duration of ER visit from an emergency department perspective or the duration of hospitalization from a
hospital's perspective. Society and third-party payers may have very different time horizons. The Panel on
Cost-Effectiveness in Health and Medicine recommends performing analyses from the societal perspective
[12]. In contrast, from the payer's perspective, the only relevant costs are those that occur during the time in
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which the payer is responsible for the patient. Even third-party time horizons may be different for different
parties. For example, Sonnenberg et al [13] evaluated strategies for prevention and treatment of colorectal
cancer and inferred that colonoscopy has low incremental cost-effectiveness ratio compared with other
screening tests. Lewis [14] observed that, although, their analysis was from the perspective of third-party
payers, yet their time horizon was the lifetime of the patient. For third-party payers, including Medicare, the
strategy of screening colonoscopy every 10 years incurs large up-front costs in exchange for reduced future
costs of care for colorectal cancer. Further, Lewis noticed that from the perspective of third-party payers
other than Medicare, the time horizon may be too long. However, even Medicare has odd "scoring systems"
that reflect budgetary and cash flow constraints and effectively conducts economic evaluation over short
time horizons and high effective discount rates.
Costs and patient outcomes should be measured over the same time horizon. In addition, regardless of the
perspective taken, the time horizon of cost-effectiveness analysis should be of sufficient length to capture all
positive and negative patient outcomes affected by the interventions. For example, in chronic diseases such
as HIV, the benefits of the intervention may be realized over a lifetime for the recipients of the intervention.
Data obtained from a trial should be carefully extrapolated to estimate cost and effectiveness over a long
time horizon. In a study of early zidovidine therapy for patients with HIV [15], data showing benefit of the
therapy observed over one year was extrapolated for cost-effectiveness analysis. However, after 3 years,
there was no difference in life expectancy noticed irrespective of the intervention received by patients. The
extrapolated cost-effectiveness of the therapy turned out to be erroneous.
Time horizon plays an important role in some of the published cost-effectiveness analyses. In a study for the
treatment of clinically localized prostrate cancer, the addition of androgen suppression therapy to radiation
therapy was found to be "cost effective" but the magnitude of the cost-effectiveness was highly dependent
upon time horizon [16]. Another study done to assess the cost-effectiveness of bicalutamide (Casodex) as
alj uvant treatment in early prostate cancer used a time horizon of 15 years, and obtained an incremental
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cost-effectiveness of 27,059 euros/QALY. The main factors influencing conclusions included the time
horizon and the duration of bicalutamide treatment, which was set at a maximum (5 years) in the base case
[ 7]. In another study, assessing the efficacy and cost-effectiveness of standard chemotherapy and high-dose
chemotherapy with autologous bone marrow transplantation (ABMT) in metastatic breast cancer, it was
found that ABMT was the preferred approach under almost all assumptions, but the size of the benefit varied
greatly. ABMT had a survival benefit of 6.0 months at 5 years at an incremental cost of $115,800 per year of
life saved. If patients who were free of disease after 5 years had normal survival, the benefit was 18.1
months at an incremental cost of $28,600 per year [18].
In many situations, modeling may be required to examine the relationship between costs and benefits over
time to assess extended time horizons. The cost-effectiveness observed within the trial may be substantially
different from what would have been observed with continued follow-up. Therefore, modeling is used to
estimate costs and projected outcomes in chronic diseases such as diabetes, coronary artery disease or
hyperlipidemia. Modeling may be done not only to extrapolate the progression of clinical outcomes beyond
that observed in a trial, but also to translate intermediate outcomes into final outcomes. In addition, it is done
to use the evidence from additional trials, systemic reviews and meta-analyses to reflect what might happen
in a certain clinical setting or population. When the trial period is long enough, or when a subset of patients
are observed for a longer time, direct modeling of long term costs and outcomes is feasible. Parametric
survival models estimated on trial data are recommended for such projections. In cases where such direct
modeling is not feasible, it may be possible to "merge" trial data to long-term observational data in a model,
e.g., when evaluating thrombolysis in acute myocardial infarction patients as done by Mark et al [2].
However, the main requirements are that the modeling should be explicit and clear, as well as stating which
variables or parameters have been modeled rather than directly observed in a particular sample, and the
uncertainties noted.
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In addition, there may be need for discounting. Weinstein et al. [5] suggested that the reference case should
include discounting of future costs and health outcomes occurring during different time periods to their
present value, and stated that they should be discounted at the same rate. There are techniques and formulas
for discounting, and one simple approach is to multiply the cost incurred or the survival experienced in a
given future year by using the following formula: (1 + r) -', where "r" is the discount rate, and "t" is the
number of years from the current year. Weinstein et al. claimed that direct evidence on time preference for
health outcomes is consistent with a discount rate of 3%. Additionally, empirical evidence of the rate of
return on riskless, long-term securities, such as government bonds, is in the vicinity of 3% per annum. While
a 3% discount rate is the preferred rate for the reference case, it is also recommended to use 5% due to the
large number of previous studies that have used this rate, as well as 0% and 7% in sensitivity analysis. The
BMJ guidelines [ 19], on the other hand, suggest the analyst use an appropriate discount rate but leave the
choice more flexible e.g. the government recommended rate, and conduct a sensitivity analysis using other
rates,, The use of a zero discount rate for health benefits in the sensitivity analysis is also suggested, so as not
to penalize preventive programs. In addition, the discounting of health effects significantly alters cost-
effectiveness ratios. Many of these influences are inherently associated with any cost-effectiveness analysis
related to treatment of early, slowly progressing malignancies because such an analysis requires a sufficient
time horizon to include not only the treatment costs but its benefits as well.
Cost-effectiveness ratios should be calculated at various time horizons (e.g., 2, 5, 10 yrs, or as appropriate
for the disease), both to accommodate the needs of decision makers and to provide a "trajectory" of
summary measures over time. The effects of long-term health care costs not directly related to treatment
should be taken into account and assumptions used must be described and justified.
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2.4 Regression analysis
In order to extrapolate beyond trial horizon, several logical methods can be used. One method is to fit a
function to the available data, e.g., regression analysis while another method could be fitting known survival
curves observed in different populations. Regression analysis is a statistical method used to predict the value
of one characteristic from the knowledge of another. This method is also called linear regression, simple
linear regression, or least squares regression. The term linear regression refers to the fact that correlation and
regression measure only a straight line or linear relationship between two variables. The term simple
regression means only one explanatory independent variable and not multiple is used to predict outcome.
The least square method describes the mathematical method for obtaining the regression equation. It is a
way to determine the equation of the line that provides a good fit to the points when visualized in a scatter
plot graph. Besides, regression of non-linear functions is often by transforming them into functions that
exhibit linear relationships.
Regression is a method of obtaining a mathematical relationship between an outcome variable (y) and an
explanatory variable (x). Assuming a linear relationship, the equation can be represented as a straight line. If
the point where the line crosses, or intercepts, the y-axis is denoted by a and the slope of line by b, then the
equation of the regression line is
y = a + bx
The slope of the line measures the amount of change y changes each time x changes by a unit. If the slope is
positive, y increases as x increases. If the slope is negative, y decreases as x increases. In the regression
model, the slope of the population is generally represented by 1, called the regression coefficient and o0
represents the intercept of regression line. /5 and go are population parameters in regression. However, most
of the time, the points do not fall along the straight line. The regression model therefore contains an error
tenn, , which is the distance the actual values of y depart from the regression line. In summary, the
regression equation is given by
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y = o0+ flx + E
The regression equation used to describe the relationship in a sample of the population is commonly written
as
= go + fix
Figure 2: Regression and least squares method
solid dots = data points, solid line = regression line
For a given value of x, say x*, the predicted value y* is found by extending a horizontal line from the
regression line to the y-axis as in Figure. The difference between the actual value for y* and the predicted
value, e*=y*-y*', can be used to judge how well the line fits the data points. The distances e, calculated for
all points, is a measure of the failure of the line to fit the actual data points. The least squares method
determines the line that minimizes the sum of the squared vertical differences between the actual and
predicted values of the y variable; i.e., f0 and I, can be obtained so that E(y-y') 2 is minimized. The formulas
for fo and f, are found using differential calculus and in terms of the sample estimates these formulas are
i,= E(x-xbar) (y-ybar)/E(x-xbar) 2
30 =ybar -l 1xbar
T]he least squares regression line satisfies two conditions:
1. e = 0, that is, there is a degree of symmetry of points about the line
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Least Squares Regression Line
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2. FE e2 is as small as possible, that is, the sum of squares of the deviations about the line (hence, least
squares) is minimized.
There is only one straight line that will fulfill all the conditions described above and this has a slope or
'regression coefficient' b given by the equation.
The regression equation includes assumptions of homogeneity or homoscadasticity and linearity. For each
value of x variable, the y variable is assumed to have a normal distribution, and the mean of the distribution
is assumed to be the predicted value, y'. In addition, no matter the value of the x variable, the standard
deviation of y is assumed to be the same. Thus one can imagine a large number of individual normal
distributions of the y variable, all of equal sizes, one for each value of x. The assumption of this equal
variation in the y's across the entire range of the x's is called homogeneity. The straight line or linear
assumption requires that the mean values of y corresponding to various values of x fall in a straight line. The
values of y are assumed to be independent of one another.
Since the regression equation computed for one sample of observations is just one estimate of the true
population regression equation, choosing other samples from the population will lead to regression equations
that vary from one sample to another with respect to both their slopes and their intercepts. An estimate of
this variation is symbolized Sy.x and is called the standard error of regression or the standard error of the
estimate. It is based on squared deviations of the predicted y's from the actual ys and is found as follows:
Sy.x=(y-y')2/(n-2)
Correlation is a method of describing relationship between two variables. For the purpose of correlation,
both variables are dependant. Statistician Karl Pearson, in 1902, proposed the 'product moment correlation
coefficient' (given the symbol r) (Table 2). The denominator of r contains the sums of squares of the x and y
values, that is, it is the square root of the product of the variations in x and y measured separately. The
numerator of r is the 'sums of products', that is, the sum of the deviations of the products of the x and y
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values from their mean. Hence, r is the ratio of the joint variation of the two variables to the product of their
individual variation. There is a considerable similarity between the equation for the slope b and that for
Pearson's r. The numerator is the sums of products as before but the denominator is the sums of squares of
the x values alone. Hence, the slope of the line b is the ratio of the mutual variation of x and y to that of
variation of the x values.
The correlation coefficient varies from a perfect positive correlation (+1) to a perfect negative correlation
(-1). When r = +1, all the data points will lie on a straight line of positive slope and when r = -1, all the data
points will lie on a straight line of negative slope. By contrast, when r = 0 no linearity is present and the data
points are scattered more or less randomly. Intermediate values of r result from data points scattered around
a fitted line; less scatter when r is close to 1 or -1 and a greater degree of scatter when r is close to zero. If
there is a significant relationship between x and y that is non-linear, then the value of 'r' will be smaller and
some curvilinear relationships, especially if they deviate significantly from a straight line, could result in a
non-significant r.
Having calculated r from the data, its absolute value, ignoring the sign, is compared to the distribution of the
correlation coefficient to test the degree of significance and to obtain a p-value. Pearson's correlation
coefficient has n - 2 degrees of freedom because the means of both the x and y values have to be calculated
from the data and therefore, there are two restrictions in the calculation of r. It is important to test the
'goodness-of-fit' or 'validity' of the line, that is, to determine how well the line fits the data points. The
square of the correlation coefficient r2, also known as the 'coefficient of determination', measures the
proportion of the variance associated with the y values that can be accounted for or 'explained' by the linear
relationship of y on x.
22
2.5 Survival analysis using actuarial method
Analysis of survival times can be done by actuarial or life table analysis (also called Cutler-Edere method).
Astronomer Edmund Haley (of Haley's Comet fame) first used life tables in the 17 th century to describe
survival times of residents of a town. The actuarial method is computationally easier than the Kaplan -Meier
product limit method. When analysis of survival is done while some patients in the study are still living, the
observations on these patients are called censored observations. In my thesis, I have not used censored
observations.
Table 3: Life table for the total population: United States, 2001
Time Probability Number Number Person- Total Expectation
interval of dying surviving to dying years number of of life at
ages x between age x between lived person- age x
to x+1 ages x ages x to between years
and x+1 x+1 ages x lived
to x+1 above age
X
Age qxIx dx Lx Tx ex
0-1.. 0.006842 100,000 684 99,404 7,716,990 77.2
1-2.. 0.000518 99,316 52 99,290 7,617,586 76.7
2-3.. 0.000342 99,264 34 99,247 7,518,296 75.7
Survival analysis using life table of a population [20] is shown in Table 3 and is explained below:
1. Time interval ages x to x+1 (Age): The first column (Table 3) shows the age interval is the period
between the exact two ages stated. For example, 1-2 means the one-year span between 1 st and 2 nd birthday.
2. Probability of dying during age interval (qx): For age interval 1-2 years, the probability of dying is
0.000518. The "probability of dying" column forms the basis of the life table; all subsequent columns are
derived from it.
3. Number living at beginning of age interval (lx): I use lx to indicate the number of persons, starting with
the original cohort 100,000 live births, who survive to the exact age marking the beginning of each interval.
Each lx value is computed by subtracting the number dying during the interval for the previous age interval
from the lx for the interval
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4. Number dying during age interval (dx): The number of persons of the original 100,000 who die during
each successive age interval denoted by dx.
5. Person-Years Lived in interval (Lx): The symbol Lx designates the totality of years lived by the survivors
of the original 100,000 between the ages x and x+n.
6. Total number of Person-Years (Tx): The symbol Tx denotes the total number of person-years lived by lx
survivors from year x to death. It is obtained by cumulating the person-years lived in the intervals.
7. Expectation of Life (ex): It is the most valuable feature of a life-table. It denotes life expectation, the
average number of years of life remaining to those who survive to the beginning of the age interval. It is
calculated by dividing the number of person-years lived after a given age, by the number who reached the
same age.
2.6 Regression of survival data
Fitting complex forms of survival data by regression is often difficult and usually entails considerable
computation. Fortunately, after some manipulation of the data, it is possible to apply a more familiar linear
regression analysis. For example, the relationship y=acbx will upon taking logarithms, give log y = log a +
bx(log c). Defining new values as follows y' = log y, a' = log a, b' = b(log c) gives the linear relationship
y'=a' + b'x to which linear regression techniques can be applied. In other words, one fits a linear regression
of log y on x.
When data are arranged in a life table analysis, a regression method for survival distribution fitting can be
used as suggested by Gehan and Siddiqui [21]. They suggested considering four theoretical distributions for
such regression: exponential, Weibull, Gompertz and linear exponential. The hazard functions are estimated
by a non-parametric method for each interval and parameters of distribution are then estimated by the
mrnethod of weighted least squares. The best fit among the four distributions is selected by comparing the
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likelihood values of the observed data under the four distributions. The distribution that gives the largest
likelihood value provides the best fit.
2.7 Hazard function
It is also called the conditional failure rate, instantaneous mortality rate, force of mortality, condition
mortality rate or age specific failure rate or the incidence density function. The hazard function, h(t), is the
probability of the occurrence of an event in a small time interval, per unit time, on the condition that the
event has not occurred before the interval. When considering the event of death, it is conditional on the
patient being alive at the beginning of the interval.
h(t) = number of patients dying in the time interval starting at time t
(number of patients surviving at t) ( interval width)
h(t) = number of patients dying per unit time in the interval
(number of patients surviving at t)
hi(t) = number of patients dying per unit time in the interval
(number of patients surviving at t) -1/2 (number of deaths in the interval)
In terms of failure, it is the probability of failure during a very small time interval assuming that the
individual has survived to the beginning of the interval. From the definition, it follows that the hazard
function is the probability density function divided by the survival function. Therefore, h(t)=f(t)/1-
F(t)=:f(t)/S(t) where F(t) is the cumulative failure function and S(t) is the cumulative survival function.
The hazard functions of these four distributions are as following:
1. Exponential: h(t) = X, X>O
2. Weibull: h(t) = X"y t, X', y>O, X' = =X
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3. Gompertz: h(t) = exp(X + yt), h(t) >0
4. Linear Exponential: h(t) = X + yt, h(t)>0
Transforming hazard functions: Interestingly, these four distributions share a common property regarding
the hazard function. The hazard function h(t) or its logarithmic transform logeh(t) is a linear function of t or
loget.. Considering this property, these four models can be rewritten as
1. h(t) =X
2. logeh(t) =logeh(yX') + (y-l)loge(t)
3. logeh(t) = X + yt
4. h(t) = X+ t
To simplify, let y= h(t) or logeh(t), then the models can be written in the general form:
y=bO+blx
For exponential model
y=h(t) bO=X bl=0
For Weibull model
y=logeh(t) b0=logeh(yX') bl=y-l x=loge(t)
For Gompertz model
y=logch(t) bO=X bl=y x=t
For linear exponential model
y=h(t) bO=X b l=y x=t
Therefore, if x and y are known, the coefficients bO and b 1 can be easily estimated. The advantage of the
data arrangement in life table fashion is that the hazard function can be estimated and t can be taken as the
midpoint of the interval. Thus, for the nth interval, y,= bO+b 1 x, where y, is the estimated hazard function or
its logarithm and x, is the midpoint of the interval or its logarithm. Having Yn and xn for each interval, I can
estimate bO and bl.
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Similarly, the survivorship functions for the four models are as following:
For exponential model
1. S(t)= exp(-Xt)
For Weibull model
2. S(t)= exp[-(Xt)
For Gompertz model
3. S(t)= exp{-exp(X)/-yfexp('t)-1]}
For linear exponential model
4. S(t)= exp[-(Xt+l/2yt 2 )]
Substituting the least-square estimates of X and y, I can obtain estimated values of logeL for each model.
The best fit among the four distributions is selected by comparing the likelihood values of observed data
under the four distributions. The idea is to maximize the likelihood or log-likelihood function or to minimize
the negative log-likelihood function while choosing a model. For a given prediction of survival and life table
as in Table 3, the likelihood function is defined as:
L = (qx)d x (px)l x-dx
Tlhat is, one may calculate the likelihood by multiplying the chance of dying raised to the number of deaths
and the chance of living raised to the number of survivors for each interval. Given the respective model, the
larger the likelihood of the model, the larger is the probability of the dependent variable values to occur in
the sample. Therefore, the greater the likelihood, the better is the fit of the model to the data.
Having chosen the best fitting model among the four, a 'goodness-of-fit' test can be performed. This is done
by considering twice the difference between the log-likelihood under the best fitting model and the sample
data. It follows approximately the chi square distribution with n- 1-k degrees of freedom, where n is the
number of intervals and k is the number of parameters estimated in the model (k=l for exponential and k=2
for Weibull, Gompertz and linear exponential models).
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2.8 Survival curves and the calculation of life expectancy
A, survival curve graphs the fraction of patients in a cohort who are alive at different times. The survival
function, S(t), is also referred to as survivorship function or cumulative survival rate and can be expressed as
the probability (p) that an individual survives a time T longer than an arbitrary time t. By definition, the
initial survival at time zero is one and that at time infinity is zero.
S(t) = P( an individual lives longer than t)
=P (T>t)
=1 for t = 0
= 0 for t= oo
S(t) = number of patients surviving longer than t
total number of patients
Figure 2b. Survival curve for 65-year old based on US life tables
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For example, Figure (2b) shows a survival curve based on survival at age 65 from US life tables. The area
under the curve equals the average life expectancy for any member of the cohort. Thus, the integral of a
survival function equals life expectancy.
Life Expectancy= . S(t)dt
Life expectancy can be approximated by summing the areas of consecutive rectangles as shown in Figure
2b. Unfortunately, although survival functions such as Gompertz provide a good fit to actual survival curves,
there is no simple closed form solution to the integral of Gompertz and other models of survival. Thus,
making estimates of life expectancy using these models is difficult. Markov modeling is, therefore, used for
estimating life expectancies.
2.9 Markov model
Markov models are built to model events over long time horizons e.g. lifetime of a patient. A Markov
process describes a state-transition model to project prognosis over time [22]. Markov models are especially
useful for modeling prognosis when the risk recurs repetitively over a long period of time, when the
likelihood of an event changes over time or when the utility of the associated outcome depends on when the
event occurs. A Markov model consists of a small set of clinical states to describe the possible health states
of a patient. A cohort of identical patients begins the process assigned in one or sometimes several states at
the start of the simulation (time zero). A clock runs at a fixed rate, and with each tick of the clock, patients
move from one state to another state based on "transition probabilities," that summarize a base of knowledge
or assumptions about prognosis. Since only a single effective transition occurs in a given clock cycle of a
Markov model, it is important to have a sufficiently short cycle time to maintain fidelity. Transition
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probabilities based on annual event rates will be converted to monthly rates and from those rates to monthly
transitional probabilities.
With each clock tick, the membership of each state is recorded, providing a "trace" or curve of each state's
mnembership over time. A basic assumption of such a model is that only a single state-transition can occur
when moving from one cycle to another. The basic property of a Markov model is that it has no memory of
previous states, which is termed the Markovian assumption. All patients in the same health state have the
same prognosis regardless of their history. The model also estimates that costs associated with being a
member of each health state. By multiplying the state's membership by its estimated costs, the annual and
cumulative cost of healthcare, over time, for the entire cohort can be calculated. Simulations will be run
until the entire initial cohort has transitioned to the absorbing state, such as the "Dead" state. An "absorbing
state" means the probability of transition to another state is 0.
In a model consisting of only two states, "Alive" and "Dead," the trace of the "Alive" state over time would
describe the cohort's survival curve. The characteristic S-shaped curve of a healthy population was
described over a century ago by Gompertz and can be produced using a function of the form (A*exp(Bage)) to
describe the instantaneous (as opposed to the average) mortality rate at each attained age of the cohort.
Given a projected survival curve, one can calculate life expectancy (or a cohort's average survival) by
calculating the area beneath the survival curve. In performing such calculations of life expectancy, the so-
called "half-cycle" correction is included, to compensate for the fact that observations are made at the
beginning or end of each cycle, and not continuously. If the cycle length is sufficiently short, the need for a
half cycle correction disappears.
2.10 Overview of programming languages and R
Interpreted versus compiled languages: Like Java and Basic, R is an interpreted language, in which
individual language expressions are read and then immediately executed [23]. The R interpreter carries out
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the actions specified by the R expressions. It is always interposed between R functions and the machine
those functions are running on.
Fortran and C, by contrast, are compiled languages, in which complete programs in the language are
translated by a compiler into the appropriate machine language. Once a program is compiled, it runs
independently of the compiler.
The great advantage of an interpreted language such as R is that it allows incremental development and,
therefore, is an excellent prototyping tool. Programmers can write a function, run it, write another function,
run that, and then write a third function that calls the previous two. They can create an empty shell of a
function, add features as desired, and relatively quickly create a working version of virtually any application.
T:he disadvantage of an interpreted language is related to the requirement of an interpreter and the overhead
associated with it. Compiled code runs faster by optimizing the machine code to perform the required steps
in the most efficient manner and requires less memory than interpreted code.
Object-oriented programming: Traditional computer programming deals with programs, which are
sequences of instructions that tell the computer what to do. In the sense that a computer language is a
language, programs are verbs. Object-oriented programming, by contrast, deals largely with nouns, namely,
the data objects that traditional programs manipulate. In object-oriented programming, a programmer thinks
about a type of object and tries to imagine all the actions that can be performed on objects of that type. The
programmer, then, defines the actions specifically for that type of object.
R is an object-oriented programming language, and takes full advantage of the powerful concepts of classes
and methods. The advantages of object-oriented programming are not evident when writing a single function
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for a particular purpose. Instead, the advantages arise when designing a large system that will do similar, but
not identical, things to a variety of data objects.
Object-oriented programming uses the data being acted upon to determine what actions take place. Thus, a
common synonym for object-oriented is data-driven. Because the actual actions are determined by the data,
the commands or function calls are, in effect, simply requests from the user to the data: "print yourself',
"summarize yourself'. These requests are generally expressed as calls to generic functions. A generic
function, such as print or plot, takes an arbitrary object as its argument. The nature of the object then
determines how the action specified by the generic function is carried out. The actual actions are performed
by defined methods which implement the action called for, by the generic function for a particular type of
data. Most generic functions have default methods which are used if no more specific method can be found.
For example, if you type the expression print(myobject) with myobject a factor, R will print myobject using
the method print.factor. If myobject is a vector, the printing is performed by print.default.
Methods are named using the convention action.class, where action is the name of the generic function, and
class is the class to which the method is specific. Thus plot.factor is the plot method for factors, and
is.na.data.frame is the missing value test method for data frames. R determines which method to use for a
given object by looking at the class attribute of the object, if it exists. If the class attribute is missing, the
default class is assumed. For example, factors are identified by class "factor", while vectors have no class
attribute, so are of class default.
A class attribute is just a character vector, and it can be of any length. The first element in the class attribute
is the most specific class of the object. Thus, for example, an ordered factor has class attribute c("ordered",
"factor"), and is said to have class ordered. Subsequent elements in the class attribute specify classes from
which the specific class inherits.
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Inheritance is a powerful concept in object-oriented programming, because it lets a user define a new class
with only the features needed to distinguish it from classes from which it inherits. Thus, ordered factors are
simply factors for which the levels have a specific ordering
History and uses of R: It is a language and environment for statistical computing and graphics. R is a
different implementation of S, which was developed at Bell Laboratories by John Chambers and colleagues.
R. is an integrated suite of software facilities for data manipulation, calculation and graphical display. It
includes an effective data handling and storage facility and a suite of operators for calculations on arrays
especially matrices. It provides a large, coherent, integrated collection of intermediate tools for data analysis.
R has graphical facilities for data analysis and can display either on-screen or on hardcopy. One of R's
strengths is the ease with which well-designed publication-quality plots can be produced, including
mathematical symbols and formulae where needed. It can be regarded as a well-developed, simple and
effective programming language that includes conditionals, loops, user-defined recursive functions and input
and output facilities. R is an environment within which statistical techniques are implemented. R can be
extended via packages. For computationally-intensive tasks, C, C++ and Fortran code can be linked and
called at run time. Advanced users can write C code to manipulate R objects directly. It compiles and runs
on a wide variety of UNIX platforms, Windows and MacOS.
Programming tools in R: There are two main tools for developing R programs: the Commands window and
Script windows. The > prompt in the Commands window indicates R is ready for your input. You can now
type expressions for R to interpret. The Commands window button on the Standard toolbar window, simply
use the close window tool on the top right of the window. The command > q() will close down R altogether.
Script windows, on the other hand, do not execute each statement as it is typed in, nor is there a prompt
character. They are for developing longer R programs, and for building programs from a variety of sources,
such as the history log.
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The R graphical user interface: R's graphical user interface is an object-oriented system. Graph elements,
menus, and dialog components are all objects which may be manipulated. The two most common actions to
perform on an object are creating the object and modifying the object. Objects may also be copied, moved,
and removed. Documents such as graph sheets and scripts may be created, opened, viewed, saved, and
removed. Graphical user interface objects persist in memory for the duration of an R session. Interface
elements such as menus and dialogs are automatically saved to disk at the end of a session. The user is
FIGURE 3. Graphical user interface for R
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prompted as to whether graph objects are to be saved as the end of a session. R graphical user interface is
available for windows. A Java based graphic user interface is also available.
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3. MATERIALS AND METHODS
3.1 Data sources
First, survival data were extracted from US life tables[20] to derive survival function for two competing
strategies of a hypothetical model. Assuming that the new and usual treatment strategies resulted in a
survival identical to persons 5 and 10 years older (than age 64) respectively; the survival data starting at age
69 years and 74 years were obtained for this hypothetical model for the duration of 10 years (Appendix 1).
In addition, for the real data model, 15-year survival data were obtained from a published trial evaluating the
strategies of thrombolysis in patients with myocardial infarction [2]. This study included 14-year data on
survivors of myocardial infarction in the Duke Cardiovascular Disease Database. Finally, for the theoretical
overview model, cumulative differences in cost and effectiveness of the two strategies were assumed to: 1)
decrease, 2) remain constant or 3) increase over time and incremental cost-effectiveness ratios were obtained
over varying time horizons.
3.2 Data analysis software and environment
Data analysis was done using R (Computing Version 2.1.1 (2005-06-20)). R is an integrated suite of
software facilities for data manipulation, calculation and graphical display. It includes an effective data
handling and storage facility and a suite of operators for calculations on arrays especially matrices. It
provides a large, coherent, integrated collection of intermediate tools for data analysis. It can be regarded as
a well-developed, simple and effective programming language that includes conditionals, loops, user-
defined recursive functions and input and output facilities. R is an environment within which statistical
techniques are implemented.
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I used R scripts for regression analysis and fitting of survival curves (Appendix 4). First, an object table was
created by reading in a .csv file. This table was then manipulated to get the hazard rate. A linear regression
model was developed by using linear model (lm) function and regression of hazard rate and time or their
logarithm were performed as appropriate for the chosen model by applying user-defined functions e.g.
Gompertz or Weibull (Appendix 3). Statistics for significance of regression and R2were obtained by
implicit R functions. By using R's graphical interface, a fitted survival curve was plotted. User-defined
functions for likelihood estimation, its logarithm and maximal likelihood estimation were used for model
selection. Goodness of fit was also obtained by user-defined functions. A hierarchal, object-oriented
environment in R leads to a graphical interface (Figure 4) displaying use of functions, models and objects
including graphs and tables.
FIGURE 4. Graphical user interface showing object-oriented elements of R
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3.3 Estimation of effectiveness and costs
3.3.1 Hypothetical model
I compared two strategies for patients: undergoing the new therapy or usual therapy. As stated above, I
extracted survival data from US life tables for 10 years starting at age 69 for the new treatment strategy and
age 74 for the usual treatment strategy. I created a hypothetical model of a trial with survival data in a life
table format as previously shown (Table 3).
In addition, I used simple linear regression of the interval start time and hazard rate or their logarithm based
on the model chosen. The statistical formulae as shown in Table 4 were encoded in R for calculations and
plotting graphs. Other relevant statistics were available as functions in R.
Table 4. Regression and correlation - statistical tests and formulae
Statistic Symbol Formula Purpose
Pearson's correlation r Exy/v/jx2Ey2 Linear relationship between x and y
Regression coefficient b Exy/Ex2 Measure change in y per unit of x
Standard error of b sb sy.x/Ex2 Enables 't test of b (t = b/ sb)
Prediction of y* SEy* sy.x l/n + x 2 /Ex 2 ) CI for mean y at specific x
Prediction of y SEy sy.x vl + /n + X2/X 2) CI for individual y at specific x
CI[ = confidence interval, n = number of pairs of observations, Ex2 = sums of squares of x, Ey2 = sums of
squares of y, Exy = sums of products of x and y, sy.x = mean square deviation from regression
Using R scripts, I calculated the hazard functions over 10 years and transformed them to linear equations in
terms of time t or log t, as needed, for exponential, linear exponential, Weibull and Gompertz distributions
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and fit hazard functions to the data using the least-squares linear regression method. Then, the likelihood of
different survival models was estimated, and the model yielding the maximal likelihood estimate was
selected as the best fitting model. The goodness-of-fit of the model was then estimated by taking twice the
difference between the log-likelihood under the best fitting model and the sample data. The initial and the
extrapolated data were compared over different time horizons: 5-, 10- and 15-year in addition to lifetime.
I fit four commonly used hazard functions as following:
Exponential Regression: In this model, the hazard function h(t) is a constant, h(t) = X. I calculated the mean
of the hazard function to obtain k
Linear Exponential Regression: The hazard function h(t) in this model is a linear function of time t,
h(t) = X + Yt. I performed linear regression to determine the slope y and intercept X
Gompertz Regression: Characteristically, in the Gompertz model, the hazard function h(t) is a function of
time t, of the form h(t) = exp(X+ ), h(t) >0. This can be transformed to a linear relation by taking the
logarithm of h(t): logeh(t) = X + yt. I performed linear regression to determine the slope y and intercept k
Weibull Regression: In the Weibull model, the hazard function h(t) is a function of time t, of the form
h(t) =: X-y te', X', y >0, X' = X". This can be transformed to a linear relation by taking the logarithms of h(t) and
t: logeh(t) =(('y-l)loge(X) +loge('yX) + ('y-l)loge(t). I performed linear regression to determine the slope
('- 1) and intercept (3y-l)loge(X) +loge(yX).
For a given prediction of survival and life table, the likelihood function is given by
L = H [1-(S(ti+,)/S(ti) )]di[S(ti+)/S(ti)]nidi
That is, one may calculate the likelihood by multiplying the chance of dying [1-(S(t +l)/S(ti) )] raised to the
number of deaths (di) and the chance of living raised[S(ti+l)/S(ti)] to the number of survivors (ni-di) for each
interval (i). Then, the survival model yielding the highest likelihood may be selected as the best fitting
model for the data. It is mathematically equivalent to the maximal likelihood function.
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3.3.2 Model with real data
I extracted 15-year survival data published in a model used for cost-effectiveness study of thrombolytics in
paltients with myocardial infarction [2] to show applicability to real data. For further exploration, I excluded
the first-year acute hazard rate in order to model chronic disease rather than acute mortality.
I created a hypothetical model of a trial with survival data in a life table format as shown below:
Table 5: Modified life table method for a trial
Number Number Proportion Proportion Cumulative
Surviving dying Terminating Surviving Proportion
Interval to between Surviving at
Start Time Age x ages x to x+1 End
Ix dx x x sx
dx/(Ix-(dx/2)) 1-qx (px*p(x-1))
0 100.000 2.266 0.0229197 0.97708 0.9770803
1 97.734 2.411 0.0249811 0.975019 0.9526718
However, when using the life table method to calculate life expectancy from a given survival curve in the
real data model, one has to modify the above method as shown in Table 5. This is because the probability of
dying between ages x and x+1 is not explicit when deriving data from a survival curve. Assuming there is no
withdrawal of patients, the first column shows the start of the interval. The second column (lx) shows the
number of patients at the start of an interval, the third column (dx) shows the number of patients dying
during the interval. The column (qx) gives the proportion terminating. The actuarial method assumes that the
patients die randomly through the interval; therefore on an average, they die half way during the time
represented by the interval. This method gives patients, who die during the interval, credit for being alive for
half of the period. This assumption is of less consequence when short intervals are analyzed. However,
considerable bias can be introduced if the intervals are large. The proportion surviving is then calculated in
column (px). In the end, cumulative proportion surviving (sx) is calculated by multiplying the proportion
surviving in the interval x to x+1 and the proportion surviving in all previous intervals. Life expectancy can
be calculated based on this method.
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3.3.3 Overview model
I explored estimation of incremental cost-effectiveness ratios for the two strategies A and B over different
time horizons: 1-, 5- and 10-years. A theoretical model was developed for costs and effectiveness of the two
strategies. Assuming that the cumulative differences in cost and effectiveness of the two strategies: 1)
decrease 2) remain constant or 3) increase, I obtained incremental cost effectiveness ratios for the different
time horizons for the two interventions. Thus, I developed a matrix of incremental cost-effectiveness ratios
for different time horizons based on the model.
3.3.4 Annual versus cumulative difference in costs and survival
Annual cost of strategy A refers to the mean cost over a year for the strategy. The difference between the
annual cost of strategy A and B is the difference in cost of the strategy A as compared with B for a given
year. Cumulative cost is the sum of costs over a given time horizon for a strategy. Cumulative difference in
cost at a given time horizon is the sum of the differences of cost of strategy A as compared with strategy B
in the preceding time. Surviving fraction of patients is the fraction of cohort surviving at a given time as
compared with the cohort at the start time t=O and therefore the survival function S at time t= 0 is depicted as
S(0)=:1. As time approaches infinity, surviving fraction tends to 0. In other words, as time increases,
surviving fraction decreases and becomes 0 over a "long enough" time duration. The surviving fraction when
plotted over time depicts the survival curve. Life expectancy can be obtained as the cumulative survival over
time, or graphically as the area under the survival curve for a strategy. The cumulative difference in
surviving fraction of two competing strategies A and B, i.e. the difference in areas under the survival curves,
is the cumulative difference in effectiveness or life expectancy of strategy A compared with strategy B.
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3.3.5 Distributions of cost
Decreasing cumulative difference in cost: Let us follow costs of two strategies A and B over 10 years. The
annual cost for each year of a hypothetical trial is shown in Figure 5a. With increasing time, the annual cost
of strategy A, which is initially higher than strategy B, falls below the annual cost of strategy B. Thus, the
difference in incurred cost of strategy A over Strategy B decreases each year and becomes negative, i.e.,
strategy B has a higher annual cost than strategy A as time in the trial progresses. This leads to a decreasing
cumulative difference in cost over increasing time horizon. In addition, cumulative difference in cost
discounted at 5% is shown in Figure 5b. Discounting tends to flatten the cumulative difference in cost over
different time horizons. The cumulative difference curve becomes increasingly deep at later time horizon as
the discounting decreases to values near zero. The cumulative difference curve initially slopes up due to the
data chosen for this hypothetical model.
Figure 5a. Annual incurred cost showing decreasing difference in cost (not the absolute difference)
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Figure 5b. Cumulative difference in cost (when annual difference in cost is decreasing)
Constant cumulative difference in cost: Similarly, if I follow the costs of two strategies A and B over 10
years, the annual cost of this hypothetical trial is shown in Figure 5c. With increasing time, the annual cost
of strategy A, which was higher than strategy B in the beginning, falls to the annual cost of strategy B.
Therefore, the difference in incurred cost of strategy A over Strategy B decreases over time and becomes
zero, i.e., strategy B costs the same as strategy A. This leads to a constant cumulative difference in cost over
increasing time horizon (Figure 5d).
Figure 5c. Annual incurred cost showing cost of strategy A=cost of strategy B and constant cumulative
difference in cost
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Figure 5d. Cumulative difference in cost (when annual difference in cost = 0)
Increasing cumulative difference in cost: Figure 5e. displays the annual cost of a hypothetical trial over 10
years. With increasing time, as long as the annual cost of strategy A, remains higher than the annual cost of
strategy B, the difference in incurred cost of strategy A over Strategy B will remain positive. This leads to an
increasing cumulative difference in cost over increasing time horizon (Figure 5f).
Figure 5e. Annual incurred cost when difference in cost is positive
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Figure 5f. Cumulative difference in cost (based on positive annual difference in cost)
3.3.6 Distributions of effectiveness
Decreasing cumulative difference in effectiveness: Let us follow the fraction of patients surviving when
comparing two strategies A and B over 12 years. Survival must decrease as time increases and becomes zero
as time increases to infinity (or approximately 12 years in this case). Figure 6a. gives the fraction of patients
surviving each year of the trial as compared to survival at time t=O to 12 years. With increasing time, the
fractional survival of patients of strategy A, which was higher than strategy B in the beginning, falls below
the fractional survival of strategy B and the difference in effectiveness of patients treated with strategy A
over Strategy B decreases each year and becomes negative i.e. strategy B has a higher fractional survival
than strategy A. This leads to a decreasing cumulative difference in effectiveness or survival over increasing
time horizon. In addition, I have shown cumulative difference in survival discounted at 5% (Figure 6b).
Notice that the cost curve "flattens".
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Figure 6a. Annual effectiveness showing decreasing difference in effectiveness (not the absolute
difference)
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Figure 6b. Cumulative difference in effectiveness (based on decreasing difference in effectiveness)
LE = Life expectancy
Constant cumulative difference in effectiveness: Similarly, the fraction of patients surviving with strategies
A and B can be followed over 12 years (Figure 6c). With increasing time, the initially higher fractional
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survival of strategy A falls to the level of fractional survival of strategy B and, therefore, the difference in
survival of strategy A over strategy B decreases and becomes zero i.e. survival for strategy B is the same as
strategy A. This leads to a constant cumulative difference in survival over longer time horizon (Figure 6d).
Figure 6c. Annual effectiveness when difference in effectiveness = 0 (year 2- 10)
Str A = Strategy A effectiveness, Str B = Strategy B effectiveness, Dif. AE = Difference in annual
effectiveness
Figure 6d. Cumulative difference in effectiveness (when difference in effectiveness = 0)
LE = Life expectancy
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Increasing cumulative difference in effectiveness: Figure 6e. displays the fraction of surviving patients each
year with strategy A and strategy B. At time=O, fraction surviving for each strategy is 1. With increasing
time, the fractional survival of strategy A remains higher than the fractional survival of strategy B; therefore,
the difference in survival of strategy A over B is positive each year. This leads to an increasing cumulative
difference in survival or life expectancy over increasing time horizon (Figure 6f). However, since the
survival over extended time horizon falls to 0, the curves must eventually asymptote.
Figure 6e. Annual effectiveness showing positive difference in effectiveness
Str A = Strategy A effectiveness, Str B = Strategy B effectiveness, Dif. AE = Difference in annual
effectiveness
Figure 6f. Cumulative difference in effectiveness (when positive difference in effectiveness)
LE = Life expectancy
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4. RESULTS
4.,1 Hypothetical model
Based on the hypothetical model derived from US life tables, survival data for the two interventions were
obtained for 10 years and the hazard functions for the two interventions were derived using R scripts. The
hazard function for the new treatment arm was regressed successfully using four distributions - exponential,
linear exponential, Weibull and Gompertz distributions (Figure 7). The r2 for simple linear regression was
between 0.89 to 0.99, and test statistic for regression was significant for all four distributions. Using lifetime
time horizon, the life expectancy (in years) based on exponential model was 18.1, linear exponential model
was 12.6, Weibull model was 14.1 and Gompertz model was 12.1. Gompertz model had the highest value of
likelihood estimation and is the model of choice.
Figure 7a. Regression of hazard function of the new treatment arm in the hypothetical model
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Similarly for the usual treatment arm, the hazard function was successfully regressed to obtain the above
four distributions. The coefficient of determination (r2) for simple linear regression was between 0.89 and
0.99, and the test statistic for regression was significant for all four distributions. Using lifetime time
horizon, the life expectancy (in years) based on exponential model was 18.1, linear exponential model was
12.6, Weibull model was 14.1 and Gompertz model was 12.1. Similar to the treatment branch, Gompertz
model had the maximal likelihood estimation and is the model of choice.
Figure 7b. Survival curves based on the new treatment arm in the hypothetical model
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U-sing a constant cost function of $100,000 for new treatment and $50,000 for usual treatment in the
hypothetical model over different time horizons, incremental cost-effectiveness ratios were successfully
obtained as shown in Table 6.
Table 6: Cost-effectiveness analysis over different time horizons
Horizon New Rx LE Usual Rx LE Delta LE Delta Cost Incremental CER
{years ) (years) (years) (dollars) (dollars/years gained)
__5 4.75 4.63 0.12 50,000 405,236
10 8.76 8.17 0.59 50,000 84,984
15 11.84 10.47 1.37 50,000 36,401
50 15.61 12.07 3.53 50,000 14,150
Rx = treatment, LE = life expectancy, CER = cost-effectiveness ratio, delta = cumulative difference
As the time horizon in consideration encompasses increased difference in the total effectiveness of two
arns, for a constant cost difference, the incremental cost-effectiveness ratios decreased as shown in Figure
8. In addition, it is interesting to note that the maximal change of incremental cost-effectiveness ratio with
time horizon when using extrapolation is considerably greater than maximal change of incremental cost-
effectiveness ratio based on different fitted models. In this case the time horizon plays a greater role on
incremental cost-effectiveness ratio than choice of the fitted model.
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Figure 8: Time horizon and incremental cost-effectiveness ratios for the hypothetical model
ICER = incremental cost-effectiveness ratio, H = maximal change over time horizon, M = maximal change
over models
4.2 Model based on real data
Data from survival of cohort of patients was extracted from the article. Based on the article data, survival
function was created over 15 years for patients treated with t-PA and the hazard function was derived. Using
least squared method, the hazard function or its logarithm was successfully regressed over the four
distributions (Figure 9a) and test statistic for regression was significant. However, the r2 for regression
ranged from 0.5 to 0.6. Using lifetime time horizon, the life expectancy (in years) from survival curves
(Figure 9b) based on exponential model exponential model was 29.5, linear exponential model was 19.3,
Weibull model was 21.5 and Gompertz model was 16.5. Using the maximal likelihood estimation, at the 15-
year data level, linear exponential model had the highest value and the model of choice.
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Figure 9a: Regression of hazard function in a model based on published data
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Figure 9b: Survival curves based on hazard function regression in the model of published data
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4.3 Overview model of effect of time horizon on incremental cost-effectiveness ratios
Cumulative differences in cost and effectiveness of the two strategies were assumed to: 1) decrease 2)
remain constant or 3) increase over different time horizons: 1, 5 and 10 years. Incremental cost-
effectiveness ratios were calculated as the ratio of cumulative difference in costs and cumulative difference
in life expectancies for the two strategies for a given time horizon. Thus, I developed a matrix of incremental
cost-effectiveness ratios for different time horizons based on this theoretical model as shown in a fixed-axis
range format in Figure (10a) below. The distribution of incremental cost-effectiveness ratios over different
time horizons in a bigger graph format can be visualized in Figure (10 b). Looking diagonally at the matrix
from top to bottom, incremental cost-effectiveness ratios remained constant over different time horizons
when the cumulative difference in cost and cumulative difference in effectiveness were in constant
proportion and behaved identically i.e. both were increasing, decreasing or remaining constant. When one
looks at the matrix horizontally, incremental cost-effectiveness ratios increased over longer time horizon
when the cumulative difference in effectiveness was decreasing as long as cumulative difference in cost was
also not decreasing at a rate greater than that of cumulative difference in effectiveness. Similarly, in the last
row of the matrix, incremental cost-effectiveness ratios decreased over longer time horizon when the
cumulative difference in effectiveness was increasing as long as cumulative difference in cost was also not
increasing at the same rate or higher i.e. cumulative difference in cost was decreasing, remaining constant or
increasing albeit at a lower rate than that of cumulative difference in effectiveness. However, when
cumulative difference in effectiveness was constant over different time horizons, incremental cost-
effectiveness ratio behaved similar to the behavior of cumulative difference in costs (as the cost component
is in the numerator of the incremental cost-effectiveness ratio formulation). When the cumulative difference
in cost was constant, the behavior of the incremental cost-effectiveness ratio was inverse to the behavior of
the cumulative differences in effectiveness.
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Figure 10a: Effect of time horizon on incremental cost-effectiveness ratios with and without
discounting (using a fixed axis-range format shown in page 55)
EdCost= cumulative difference in cost, EdEffect= cumulative difference in effectiveness, solid line (column
1 and row 1)=strategy A and strategy B, dashed line (columnl and row 1)=annual difference in strategy A
and strategy B, solid line (except column 1 and row 1)= undiscounted, dashed line (except column 1 and row
1) =discounted, ICER=incremental cost-effectiveness ratio, ($/yr gained)=additional dollars spent for each
additional year of life expectancy gained
Note: Increasing incremental cost-effectiveness ratios eventually asymptote due to finite survival and cost
disappearing when survival at a given time becomes zero.
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Figure 10b: Effect of time horizon on incremental cost-effectiveness ratios with and without
discounting
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Further the cumulative differences in cost and effectiveness above were explored with discounting for cost
and effectiveness over time. The discount rate for both cost and effectiveness was taken as 5% per year. The
distributions were plotted graphically and the effects on incremental cost-effectiveness ratios were
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visualized as shown by the dashed line in Figure (10 a and b). As compared with no discounting, there is no
change in overall behavior of incremental cost-effectiveness ratios when considering cumulative differences
in cost and effectiveness with discounting; although there is flattening of incremental cost-effectiveness ratio
noticed with discounting over increasing time horizons.
To further explore changes in incremental cost-effectiveness ratio when cumulative difference in cost and
effectiveness behave similarly i.e. both are decreasing or increasing, but are not constantly proportionate
over time, the incremental cost-effectiveness ratios, shown in the matrix in Figure Oa as ICER D and ICER
I were further explored as shown in Figure 11 a and b. incremental cost-effectiveness ratios over longer time
Figure 1 la. ICER when cumulative differences in cost as well as effectiveness are decreasing
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_ _ 
horizon decreased if the proportion of decrease in cumulative difference in effectiveness was greater than the
decrease in cumulative difference of costs and vice versa as shown in Figure 1 la. Similarly, incremental
cost-effectiveness ratios over longer time horizon increased if the proportion of increase in cumulative
difference in effectiveness was less than the increase in cumulative difference of costs and vice versa as
shown in Figure 1 lb. However, increasing incremental cost-effectiveness ratios eventually asymptote due to
finite survival and cost disappearing when survival at a given time becomes zero.
Figure lb. ICER when cumulative differences in cost as well as effectiveness are increasing
EdCost = cumulative difference in cost, dEffect = cumulative difference in effectiveness, solid line (row
l)=strategy A and strategy B, dashed line (row 1) = annual difference in strategy A and strategy B, solid line
(except row 1) = undiscounted, dashed line (except row 1) = discounted, ICER = incremental cost-
effectiveness ratio, ($/yr gained) = additional dollars spent for each additional year of life expectancy
gained, S(t) = survival at time t, LE = life expectancy
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5. DISCUSSION
This project explores the effect on incremental cost-effectiveness ratios when evaluating two competing
strategies over different time horizons by using a statistical language and environment "R" for the
methodologies of least square regression and uncensored survival analysis based on four distributions. At the
intersection of medical informatics and healthcare and technology research, this thesis tries to bring together
different methods and tools to explore the topic. The ultimate goal is to improve both health care decision
making and health care outcomes by integrating information from a variety of sources into work processes
by providing better user interfaces, extending powerful integration and navigation and developing flexible
ways to represent, acquire, structure, and use knowledge of various sorts in computer systems for task-
oriented applications. These methodologies must bridge specific applications so that the representations and
the knowledge they encode can be widely shared and reused.
In the recent past, evidence-based medicine has gained importance. The practice of evidence-based medicine
requires the integration of individual clinician's expertise with the best available external clinical evidence
from systematic research and the patient's unique values and circumstances. Evidence-based health care
further extends the application of the principles of evidence-based medicine to all professions associated
with health care, including purchasing and management. Therefore, there is a focus towards data and trials to
ascertain objectively if a therapy is effective and for what costs and how much of the effectiveness can be
quantified in general and specific populations. However, most trials have finite time horizon. This is to
capitalize on the trends of effectiveness and costs observed over smaller time horizons and then applying it
to routine clinical medicine rather than waiting for generations to prove the cost-effectiveness over a longer
time horizon. Therefore, modeling is required for evaluations of cost-effectiveness especially in the context
of limited resources and lifetime horizon or full life expectancy is now used in many analyses. However,
recently some evidence-based medicine proponents have become worried about lifetime analyses that
necessarily extrapolate beyond the durations of all trials and have begun to report cost-effectiveness using
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"hard data" available from the trial-only time-horizon. In this thesis, I hypothesized that such right-censored
analyses might affect the cost-effectiveness analysis, i.e. their incremental cost-effectiveness ratios. I used
modeling techniques to explore how extrapolation beyond a trials horizon of data might affect the
incremental cost-effectiveness ratio.
For cost-effectiveness analysis, the evaluator focuses on the costs and effectiveness of competing strategies
for analysis. In general, for a given strategy survival over time decreases while cumulative cost over time
may increase or remain constant. Since the survival follows a more predictable i.e. decreasing pattern over
time, I have focused on survival modeling and extrapolation. On the other hand, for a surgical treatment,
often costs may be upfront and then have a smaller on going follow-up cost and for a medical treatment
costs may increase, decrease or remain constant generally in a linear fashion over time. When comparing
two strategies, the cumulation or sum of the difference in cost and effectiveness over a time horizon is
considered in a cost-effectiveness analysis. This cumulative difference in cost and effectiveness may
increase, decrease or remain constant over a time horizon.
In this thesis, first I used a hypothetical model based on US life tables to lay down the basic tools and
techniques to be used. Gehan and Siddiqui have previously described the methodologies of integrating
regression and survival analysis [17] for the purpose of selection of a model that can be used for
extrapolation of survival. The idea is to use survival data in a life table format to derive the hazard function
or it transformation and use it for regression. Based on this regression, fitted survival functions in different
distributions are obtained. Then, the best-fitting model for extrapolation over different time horizons is
chosen. In the hypothetical model, the hazard function was successfully regressed and survival functions
were derived based on exponential, Weibull, Gompertz and linear exponential models. Then, maximum-
likelihood estimates were used to choose the best fitting model from among alternative survival functions
rather than making an arbitrary choice. This methodology may lead to a more accurate extrapolation of
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survival data within decision-analytic models. Since survival of general population closely fits a Gompertz
finction, the hypothetical model fitted the Gompertz curve the best.
In the second model, I used published data, to apply the methodology developed and used previously in the
hypothetical model. Again, least-square regression was performed on the hazard function or its
transformation and then using four survival distributions, the best-fitting model was selected using the
maximal likelihood method. The survival data was then extrapolated in different time horizons beyond the
trial time. Real survival data from patients undergoing competing interventions may fit any distribution. In
this model based on published data from Duke Cardiovascular Database, the distribution best fitting survival
distribution was linear-exponential. However, since the publication did not explicitly display the survival
curve of the competing strategy the incremental effectiveness over different time horizons could not be
obtained.
To further generalize my observations, I developed an overview model. A graphical matrix was developed
to visualize the interplay of cumulative differences in costs and effectiveness and to develop an intuition of
how incremental cost-effectiveness ratios behaved over different time horizons and what role discounting
plays in modifying this behavior. In the overview model, a matrix of incremental cost-effectiveness ratios
over different time horizons, based on decreasing, constant and increasing cumulative differences in cost and
effectiveness was obtained. To show the effect of difference in the scale used, the graphs are presented it in
two different formats.
With the exception of similar behaving cumulative differences in cost and effectiveness in constant
proportion leading to unchanged incremental cost-effectiveness ratios, incremental cost-effectiveness ratios
decreased when cumulative difference in costs was decreasing and increased when cumulative difference in
costs was increasing. When the cumulative difference in cost was constant, the behavior of the incremental
cost-effectiveness ratio was opposite to the behavior of the cumulative differences in effectiveness. Even
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with discounting, the incremental cost-effectiveness ratios showed behavior similar to that obtained from
cumulative differences in cost and effectiveness without discounting. Thus, exploring the effect of time
horizon on incremental cost-effectiveness ratios can give us an explicit understanding when analyzing the
cost-effectiveness of two competing strategies.
From the models developed in the thesis, there are quite a few insights that can be gained. Firstly, time
horizon makes a difference in incremental cost-effectiveness ratios. In literature review of cost-effectiveness
analysis, it is common to come across analyses where the time horizon used is barely mentioned or is
defaulted to lifetime time horizon. However, as explored in this thesis, cost-effectiveness ratios may differ
considerably depending on the time horizon chosen. For example, as long as the cumulative difference in
costs is decreasing (higher than the proportion of cumulative difference in effectiveness) or the cumulative
difference in effectiveness is increasing (higher than the proportion of cumulative difference in cost), cost-
effectiveness ratios decrease over longer time horizon. Therefore, in cost-effectiveness analysis based on
competing projects over shorter time horizon and having cumulative difference in cost and effectiveness as
previously described, a project may not be selected as the incremental cost-effectiveness ratio of the project
may be high and above the arbitrary project selection threshold. Thus, the project will lose to other projects
whose incremental cost-effectiveness ratios are under the cut-off or have a lower incremental cost-
effectiveness ratio at a shorter time horizon. In such situations, a "surgical" strategy with high up-front costs
and modest up-front effectiveness may lose to a "medical" strategy with lower cumulative difference in cost
and effectiveness. Similarly, as long as the cumulative difference in costs is increasing or the cumulative
difference in effectiveness is decreasing, cost-effectiveness ratios increase. In such studies, cost-
effectiveness analysis based on shorter time horizon may be below the arbitrary project selecting cut-off and
makes the cut. Thus, edging out other projects that have high initial cost-effectiveness ratios and are under
the cut-off at a longer time horizon. Additionally, increase or decrease in cumulative difference of costs and
effectiveness affects incremental cost-effectiveness ratio. Even when, the differences in cost and
effectiveness are behaving similarly, incremental cost-effectiveness ratio may change over different time
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horizons. In addition, as seen over time, when the cumulative difference in cost increases more than the
cumulative difference in effectiveness, the incremental cost-effectiveness ratio increases over extended time
horizons. Similarly, over time, when the cumulative difference in cost decreases less than the cumulative
difference in effectiveness, the incremental cost-effectiveness ratio decreases over extended time horizons.
Discounting of cost and effectiveness dampens the magnitude of relative increase or decrease of cost and
effectiveness.
Secondly, modeling makes a difference in incremental cost-effectiveness ratios. Cost-effectiveness analysis
based on trial-only time horizon may not capture all the effectiveness or all of the costs of the project. In
case of an overall beneficial strategy that shows greater effectiveness over a long time horizon with minimal
increase in cost, (and may show minimal improvement in effectiveness in a trial-only time horizon), a trial-
only cost-effectiveness analysis will underestimate the effectiveness and, therefore, overstate the cost-
effectiveness ratio, making the therapy less "cost-effective" as it may be over an arbitrary cut-off. However,
a cost-effectiveness analysis based on trial as well as extrapolated time horizon may capture all of the
difference in effectiveness and the costs of the competing strategies, making the incremental cost-
effectiveness ratio lower than the cut-off and therefore making the strategy "cost-effective". Over a long
time horizon, an overall "ineffective" strategy may show a considerable increase in cost but minimal
improvement in effectiveness e.g. an experimental chemotherapy when compared with radiation therapy
may initially improve survival at a lower cost at 5-year time horizon, but may induce leukemia and excess
mortality over a 15-year time horizon. In such a case, a long-term time horizon will capture the entire
cumulative difference in effectiveness and costs and, therefore, resulting in a high cost-effectiveness ratio,
making the therapy less "cost-effective" over a long time horizon as it may be over an arbitrary cut-off.
However, modeling involves various assumptions and can be complicated. In many real trials, the regression
models may not fit the data well and, therefore, may not be useful in extrapolating costs and effectiveness in
a meaningful fashion. A recent article has shown that conclusion from cost-effectiveness analyses are
sensitive to choice of distribution of costs and how well a distribution fits the data is an insensitive guide to
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model choice and therefore sensitivity analysis is recommended to address uncertainty about choice of
distribution [24].
Another interesting insight in this thesis is the interaction between discounting and time horizon. In general,
discounting can be seen to mitigate the effect of time horizon on incremental cost-effectiveness ratios.
Intuitionally, with increasing discount rate, the changes in the distant future become less substantial. As seen
in Figure 1 Oa, discounting decreases the magnitude of increase of incremental cost-effectiveness ratios that
were increasing over longer time horizon and the magnitude of decrease in incremental cost-effectiveness
ratios that were decreasing over longer time horizons. In addition, as the discount rate increases, the decrease
in the magnitude of increase in incremental cost-effectiveness ratios that were increasing over longer time
horizon is greater. In other words the decrease or increase in cumulative difference in cost and effectiveness
is less steep and therefore discounting has a "flattening" effect on incremental cost-effectiveness ratios.
However, when the incremental cost-effectiveness ratio over extended time horizon is constant, it remains
constant with discounting as both the numerator and denominator (cumulative difference in costs and
effectiveness) are based on discounting (the costs and effectiveness) equally. However, since the accepted
discount rate is around 5%, from the figures, it is evident that time horizon plays a greater role than
discounting on incremental cost-effectiveness ratios in realistic cost-effectiveness analysis. Discounting also
has a dampening effect on cumulative difference in costs and effectiveness when considered over long time
horizons.
In addition, from this thesis, it reaffirms the advice to use several time horizons including lifetime while
extrapolating cumulative difference in costs and effectiveness. Different stakeholders evaluate cost-
effectiveness of competing strategies with different perspectives and over different time horizons. Since,
time horizon affects cost-effectiveness ratios considerably; it is advisable to conduct a detailed cost-
effectiveness analysis from different viewpoints. Therefore, one must evaluate cost-effectiveness ratios over
different time horizons and not just over trial-only or lifetime.
64
5.2 Limitations of study
T'here are several potential limitations to this analysis. The study evaluates retrospective data and has not
been tested on comparative prospective data. Not all survival distributions may reliably fit into these four
distributions and each may, in fact, be a combination of distributions. Since human survival is finite, the
models used in extrapolating survival should be explored with realistic constraints in mind. In addition, trial
data often requires censoring. In this thesis, I have not dealt with censored data nor have extended analyses
to using Cox proportional hazard model or survival estimation by Kaplan-Meier product limit method. As
implemented in "R", regression of survival and cost-effectiveness analyses requires significant knowledge of
the programming language
5.3 Future directions
I can use this methodology as an additional tool for evaluating the cost-effectiveness of prospective trials. It
can be a means to provide sensitivity analysis while the trial is being conducted. This study can be easily
applied to censored data. R has a "survival analysis package" with functions for survival analysis including
Kaplan-Meier product limit and Cox proportional hazard methods. In addition, by using C or java, I can
make a user-friendly interface, for direct data entry into the program, display of analysis and printing of
reports. This could also be done on a web-based interface.
5.4 Conclusion
When conducting cost-effectiveness analysis of two competing strategies, choice of time horizon can have a
substantial effect. Incremental cost-effectiveness ratio changes substantially with changes in duration of time
horizon considered. Discounting of cost and effectiveness dampens the effect of increasing time horizon.
Care must be taken in choosing the time horizon in a cost-effectiveness analysis and alternative time
horizons must be evaluated in all cost-effectiveness analyses.
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APPENDICES
Appendix A: Hypothetical model derived from US life tables
New Strategy
S Age qx Ix dx hrate
-_ 69-70 0.02266 100.00000 2.26630 0.02292
'1 70-71 0.02467 97.73370 2.41138 0.02498
2 71-72 0.02674 95.32232 2.54901 0.02710
3 72-73 0.02904 92.77330 2.69432 0.02947
4 73-74 0.03166 90.07898 2.85217 0.03217
5 74-75 0.03459 87.22681 3.01700 0.03520
6 75-76 0.03768 84.20981 3.17260 0.03840
7 76-77 0.04089 81.03720 3.31329 0.04174
8 77-78 0.04444 77.72392 3.45382 0.04545
9 78-79 0.04853 74.270101 3.60433 0.04974
Usual Strategy
S Age qx Ix dx hrate
0 74-75 0.03459 100.00000 3.45880 0.03520
1 75-76 0.03768 96.54120 3.63719 0.03840
2 76-77 0.04089 92.90401 3.79847 0.04174
3 77-78 0.04444 89.10554 3.95958 0.04545
4 78-79 0.04853 85.14595 4.13213 0.04974
5 79-80 0.05331 81.01382 4.31909 0.05477
6 80-81 0.05884 76.69473 4.51279 0.06062
7 81-82 0.06509 72.18194 4.69854 0.06728
8 82-83 0.07214 67.48340 4.86825 0.07484
9 83-84 0.07985 62.61515 4.99982 0.08317
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Appendix B: Model based on published data
A N
1
4
5
6
7
8
9
10
1 1
12
13
14
1.00000
0.96667
0.94444
0.93333
0.92222
0.90000
0.88889
0.85714
0.81111
0.77778
0.74603
0.71429
0.68254
0.65079
0.62222
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Appendix C: Programming user-defined functions in R
##Weibull -user defined function/class -function weib
weib<- function(yl, y2){
# rudimentary sanity checks...
if(length(yl) != length(y2))
stop("different lengths of input vectors")
if(length(yl) == 0)
stop("empty input")
#transformation of hazard rates
xl <- log(yl); hl <- log(y2)
#least squared regression
myreg<-lm(hl-xl)
myreg
# Gompertz-user defined function/class -function gomp
gomp<- function(yl, y2) {
nl <- length(yl); n2 <- length(y2)
# rudimentary sanity checks...
if(nl != n2)
stop("different lengths of input vectors")
if(nl == 0)
stop("empty input")
# transformation of hazard rate
xl <- yl; hl <- log(y2)
#least squared regression
myreg<-lm(hl-xl)
myreg
}
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Appendix D: R program for regression and survival extrapolation of the model based on published
data
#Script for Thrombolytics shortest
#;Shows all steps explicitly
# Read data table
dr<-read.table(file="thrl .csv",sep=",",header=T)
n<:-length(dr[,2])
lx<:-dr[l :n,2]* 100
dx<-(dr[l :n,2]-dr[2:(n+1),2])* 100
hrate<- dx/(lx-(dx*0.5))
# prob of dying
qx<-dx/lx
prl<-cbind(dr[ 1 :n, l],dr[l :n,2], qx, lx,dx,hrate)
pr<:-prl [1 :(n-l),]
x < -pr[, 1 ]
hl <--pr[,6]
c(mean(hl), sd(hl), var(hl))
#Regression using mean
yl<. <-rep(mean(hl),c(length(hl)))
# Graph for regression
par(mfrow=c(4,2))
plot(xl,hl,main ="Regression Exponential",xlab="years",ylab="hrate")
lines(xl ,yl)
#lines(xl,hl)
Psur <-(exp(-yl *xl))
Asur<:-(pr[,4])/100
kl<:-seq(O ,350)
k2<:-(exp(-k 1 *mean(h 1 )))
k3<-seq( 1,351)
k4<:-(exp(-k3 *mean(h 1)))
k5<:-(k2-((k2-k4)/2))
LE 1 <-sum(k5 [k5>0.001 ])
#5 year 10 years 15 years lifetime
H 1 <-c(sum(k5 [ 1:5]), sum(k5[ 1:10]), sum(k5[ 1:15]), sum(k5 [k5>0.001 ]))
#Graph for survival
plot(kl [1 :50],k2[1:50],main =" Survival Exponential",xlab="years",ylab="Survival fraction")
lin.es(xl,Psurl)
lines(xl ,Asur)
Li]keA<-c(NA,((Asur[2:(n-1)]/Asur[1 :(n-2)])^lx[2:(n-1)])*((1-(Asur[2:(n- l)]/Asur[1 :(n-2)]))dx[2:(n-1)]))
Li]keP 1 <-c(NA,((Psurl [2:(n- 1)]/Psurl [1 :(n-2)])^x[2:(n- 1 )])*(( 1 -(Psurl [2:(n- 1 )]/Psurl [1 :(n-2)]))dx[2:(n- 1)]))
#2 "d Model - Regression for linear exp model
n<-length(xl)
N<--n
SPxlhl <- sum(xl*hl)-sum(xl)*sum(hl)/n
SSxl <- sum(xlA2)- (sum(xl)A2)/n
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SShl <- sum(hl^2)- (sum(hl)A2)/n
hlbar <-mean(hl)
xlbar <-mean(xl)
b21<-SPxlhl /SSxl
b20<- mean(hl)-b21*mean(xl)
b21
b20
SSreg <-b21*SPxlhl
SSres <- SShl -SSreg
Shl .xl <-(SSres/(n-2))^0.5
r2 <-SSreg/SShl
Shl.xl
r2
#regression
lrn(hl-xl)
mlyreg<-lm(hl-xl)
sunmlary(myreg)
#Testing significance
MSreg<- SSreg/1
MSres <-SSres/(n-2)
F.calc <-MSreg/MSres
pf(F.calc, 1l,n-2)
qf(0.95, 1,n-2)
pf(F.calc, 1l,n-2)>0.95
F.calc>qf(0.95, 1,n-2)
#Plotting graph
plot(xl,hl,main ="Regression Linear Exponential",xlab="years",ylab="hrate")
lines(xl ,b20+b21 *xl)
#(Confidence Interval for predicted values
xk -- seq(min(x 1),max(x 1), 1)
y2hat <- b20 + b21 *xk
Syxk <-(( 1/n)+(((xk-x1bar)A2)/SSx 1)*MSres)^0.5
t.val<-qt(0.975,n-2)
Psur2<-(exp(-(xl *b20 + 0.5*(b21 *(x1 ^ 2)))))
kl<-seq(0 ,350)
k2<-(exp(-(kl*b20 + 0.5*(b21*(kl^2)))))
k3<-seq(1,351)
k4<-(exp(-(k3*b20 + 0.5*(b21*(k3^2)))))
k5<-(k2-((k2-k4)/2))
LE2<-sum(k5 [k5>0.001])
#5 year 10 years 15 years lifetime
H2<--c(sum(k5[1:5]), sum(k5[1:10]), sum(k5[1:15]), sum(k5[k5>0.001]))
#Graph for survival
plot(kl [ 1:50],k2[1:50], main ="Survival Linear Exponential ",xlab="years",ylab="Survival fraction")
lines(xl,Psur2)
lines(x 1l,Asur)
LikceP2<-c(NA,((Psur2[2:(n- 1)]/Psur2[1 :(n-2)])x[2:(n- 1)])*((1 -(Psur2[2:(n-Psur2[12:(n- 1]/Psur [ 2)]))dx[2:(n-1)]))
#Model 3 Weibull Model
xl <-log(pr[2:N, 1])
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hl <-log(pr[2:N,6])
#regression for Weibull model
n<-length(xl)
N<:-n
SPxlhl <- sum(xl*hl)-sum(xl)*sum(hl)/n
SSxl <- sum(x^2)- (sum(xl)^2)/n
SShl <- sum(hl^2) - (sum(hl)^2)/n
hlbar <-mean(hl)
xlbar <-mean(xl)
b31<-SPxlhl /SSxl
b30<- mean(h 1)-b3 1 *mean(x 1)
b3 1
b3()
SSreg <-b31*SPxlhl
SSres <- SShl -SSreg
Shl .xl<-(SSres/(n-2))^0.5
r2 <-SSreg/SShl
Shi .xl
r2
#regression
lm(hl-xl)
myreg<-lm(hl-xl)
sunmmary(myreg)
#Testing significance
M:Sreg<- SSreg/l
MSres <-SSres/(n-2)
F.calc <-MSreg/MSres
pf(F.calc, 1,n-2)
qf(0.95,1,n-2)
pf(F.calc, 1,n-2)>0.95
F.calc>qf(0.95,1 ,n-2)
#Plotting graph
plot(x l,hl,main ="Regression Weibull",xlab="log t",ylab="log h")
lines(xl,b30+b31 *xl)
garnma<-l+b31
lambda<-exp((b30-log(gamma))/gamma)
Psur3 <-exp(-(lambda*pr[, 1 ])^gamma)
# Calculating life expectamcy
kl<-seq(0 ,350)
k2<- exp(-(lambda*kl)^gamma)
k3<-seq(1,351)
k4<-exp(-(lambda*k3)^gamma)
k5<-(k2-((k2-k4)/2))
LE3<-sum(k5 [k5>0.001])
#5 year 10 years 15 years lifetime
H3<-c(sum(k5[1:5]), sum(k5[ 1:10]), sum(k5[1:15]), sum(k5[k5>0.001]))
#Graph for survival
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plot(kl [1:50],k2[1 :50],main ="Survival Weibull ",xlab="years",ylab="Survival fraction")
lines(pr[, 1],Psur3)
lines(pr[, 1 ],Asur)
#LikeP3<-c(NA,((Psur3[2:(n- 1)]/Psur3[1 :(n-2)])^1x[2:(n- 1)])*(( 1 -(Psur3[2:(n-1)]/Psur3[ 1 :(n-2)]))^dx[2:(n-#1)]))
LikeP3<-c(NA,((Psur3 [2:(n)]/Psur3 [ :(n- l)])^lx[2:(n)])*(( 1-(Psur3 [2:(n)]/Psur3 [ 1:(n-1 )]))^dx[2:(n)]))
#Model 4 Gompertz Model
xl---pr[2:n,l]
hl <-]og(pr[2:n,6])
#regression for g model
n<-length(xl)
S:Pxlhl <- sum(xl *hl )-sum(xl)*sum(hl)/n
SSxl <- sum(xl^2)- (sum(xl)^2)/n
SShl <- sum(hl^2) - (sum(hl)^2)/n
h lbar <-mean(hl)
x bar <-mean(xl)
b41<-SPxlhl /SSxl
b40<- mean(h )-b41 *mean(xl)
b4 1.
b4()
SSreg <-b4 l*SPxlhl
SSres <- SShl -SSreg
Sh]. .x 1<-(SSres/(n-2))^0.5
r2 <-SSreg/SShl
Shll .x1
r2
#regression
lrn(hl-xl)
myreg<-lm(hl-xl)
summary(myreg)
#lTesting significance
MSreg<- SSreg/l
MSres <-SSres/(n-2)
F.calc <-MSreg/MSres
pf(F.calc, 1,n-2)
qfi(0.95,1,n-2)
pf(F.calc, 1,n-2)>0.95
F.calc>qf(0.95, 1 ,n-2)
#Plotting graph
plot(xl,hl,main ="Regression Gompertz ",xlab="years",ylab="log h")
lines(x 1 ,b40+b41 *x 1 )
#Confidence Interval for predicted values
xk <.- seq(min(xl),max(xl),((max(xl)-min(xl))/n))
y4hat <- b40 + b41*xk
Syxk <-((/n)+(((xk-xlbar)^2)/SSxl)*MSres)^0.5
t.val<-qt(0.975,n-2)
gamnma<-b41
lambda<-b40
Psur4<- exp((-exp(b40)/b4 1)*(exp(b41 *pr[, 1 ])-1))
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# Calculating life expectamcy
kl <-seq(0 ,350)
k2<- exp((-exp(b40)/b41)*(exp(b41 *kl)-I))
k3<-seq(1,351)
k,4<- exp((-exp(b40)/b41)*(exp(b41 *kl)-1))
k5<-(k2-((k2-k4)/2))
LE4<-sum(k5 [k5>0.00 1])
#5 year 10 years 15 years lifetime
H:4<-c(sum(k5[ 1:5]), sum(k5[ 1:10]), sum(k5[ 1:15]), sum(k5[k5>0.001 ]))
#,Graph for survival
plot(kl[1:50],k2[1:50], main ="Survival Gompertz ",xlab="years",ylab="Survival fraction")
lines(pr[, 1 ],Psur4)
li:nes(pr[, 1 ],Asur)
LikeP4<-c(NA,((Psur4[2:(n+1)]/Psur4[1 :(n)])Alx[2:(n+1)])*(( 1 -(Psur4[2:(n+1)]/Psur4[1 :(n)]))^dx[2:(n+1 )]))
A<-c(LE 1, LE2,LE3,LE4)
A
G<-cbind(sum(log(LikeP 1[2:N]))-sum(log(LikeA[2:N])),sum(log(LikeP2[2:N]))-
sum(log(LikeA[2 :N])),sum(log(LikeP3 [2:N]))-sum(log(LikeA[2:N])),sum(log(LikeP4[2:N]))-sum(log(LikeA[2:N])))
G
exp(G)
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